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INTRODUCTION
Numerous physiological changes occur during pregnan-
cy, some of which can induce significant alterations in 
serum laboratory values. Common examples are lower 
hematocrit and hemoglobin concentrations, but the 
level of several inflammatory markers that correlate with 
the activity of inflammatory bowel disease (IBD) in non-
pregnant patients can also increase during pregnancy. To 
date, no optimal activity marker exists to assess the activ-
ity of IBD during pregnancy. The role of fecal calprotectin 
(FC) is conflicting in pregnant women, although it cor-
relates well with different inflammatory processes of the 
gastrointestinal tract, suggesting FC to be a useful tool in 
these patients with highly limited diagnostic procedures. 
FC also correlates with the endoscopic and histological 
grading of disease activity in IBD and is a good predic-
tor for future relapse in these patients (1). Calprotectin is 
associated with many systems, disorders, and physiologi-
cal processes including pregnancy. The production of 
S100A8 is elevated in cytotrophoblasts, placental-tissue 
macrophages, fibroblast-like cells, endothelial cells, and 
monocytic lineages. In fetal capillaries, the highest level 
can be detected during the first and second trimesters 
of pregnancy in the placenta (2). Increased levels of cal-
protectin in the amniotic fluid are related with intra-am-
niotic inflammation and a shorter interval to parturition 
(3). However, the influence of pregnancy on FC level in 
healthy pregnant women has not yet been examined.
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ABSTRACT
Background/Aims: Noninvasive activity markers are extremely important in conditions, such as pregnancy, when 
endoscopy is not recommended. The aim of this prospective study was to determine fecal calprotectin (FC) con-
centrations in healthy non-pregnant and pregnant women and in patients with inflammatory bowel disease (IBD). 
Materials and Methods: Healthy pregnant and non-pregnant women and patients with active and inactive 
IBD were prospectively enrolled in this study. Demographic and clinical parameters and clinical disease activity 
scores in patients with IBD were recorded. Blood and stool samples of every patient were obtained to deter-
mine C-reactive protein and FC levels. FC levels were measured with a quantitative lateral flow assay. 
Results: One hundred and thirty-five subjects were enrolled in the study (24 non-pregnant and 48 pregnant 
healthy women, 40 non-pregnant patients with active IBD and 23 non-pregnant patients with inactive IBD). FC was 
significantly higher in active IBD patients than in pregnant (p<0.001) and non-pregnant healthy women (p<0.001). 
No difference could be detected in FC concentrations between pregnant and non-pregnant healthy women. 
Conclusion: Since FC levels remained unchanged during pregnancy, it may be a useful noninvasive diagnostic 
tool in pregnancy for monitoring mucosal inflammation.
Keywords: Fecal calprotectin, pregnancy, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, C-
reactive protein
O
ri
gi
na
l A
rt
ic
le
Noninvasive activity markers for the evaluation of disease activ-
ity in pregnant women suffering from IBD in whom endoscopy 
should not be performed would have significant clinical rele-
vance. However, as there are no data available on the changes 
in FC during normal pregnancy, we aimed to assess FC concen-
tration in healthy pregnant and non-pregnant women.
MATERIALS AND METHODS
Between January 2013 and January 2016, 24 healthy women [con-
trols without any bowel disease and women undergoing in vitro 
fertilization cycles (mean age: 33.1 years, SD: 5.2 years)], 48 healthy 
pregnant women (pregnant subjects without any bowel disease; 
mean: 35.9 years, SD: 5.2 years) were enrolled in this prospective 
study. The second control group consisted of 40 women with ac-
tive IBD (mean: 39.6 years, SD: 15 years) and 23 women with IBD 
in sustained clinical remission (mean: 42.0 years, SD: 13.9 years) 
(Table 1). The clinical activity of IBD was assessed with partial Mayo 
(pMayo) (4,5) score in ulcerative colitis (UC) patients and with 
Crohn’s Disease Activity Index (CDAI) in Crohn’s disease (CD) pa-
tients. Endoscopy was excluded from the full Mayo score. FC and 
serum C-reactive protein (CRP) measurements were performed in 
all participants to assess the effect of pregnancy on FC concentra-
tions and CRP levels. Stool samples were collected from the first 
bowel movement in the morning. Fecal samples for FC determi-
nation were stored at −20°C until analysis. Fecal specimens were 
thawed and prepared for FC assay as described by the manufac-
turer. FC concentrations were measured with a quantitative lateral 
flow assay (Quantum Blue, Bühlmann Laboratories, Switzerland).
Statistical Analysis
Statistical analyses were performed using R statistical program 
(version 3.2.4). Descriptive parameters were shown as mean 
(SD) and/or median (range). The Mann-Whitney U test and 
Kruskal-Wallis test followed by post-hoc tests were used to 
analyze FC concentrations and CRP levels within groups. The 
post-hoc pairwise comparisons (if required) were performed 
according to the Bonferroni-Holm method. A p value of <0.05 
was considered statistically significant.
Ethics
The study was approved by the Regional and Institutional Hu-
man Medical Biological Research Ethics Committee of the Uni-
versity of Szeged (ethical approval number: SZTE-170/2011). 
The study conforms to the declaration of Helsinki. All study 
participants, or their legal guardian, provided written informed 
consent prior to study enrolment.
RESULTS
Healthy	Female	Controls	without	IBD
The mean FC concentration was 34.1 μg/g (median: : 25 μg/g,  SD: 
27.5 μg/g, range: 25.0-150.0 μg/g) in healthy controls. In healthy 
controls, we found five patients with gynecological diseases (endo-
metriosis, myoma uteri, and PCOS), two patients with hypothyreosis, 
one with hypertonia, and one with pancreas divisum. A significant 
difference (p<0.001) in FC concentrations was shown between 
patients with IBD (median: 298 μg/g, mean: 788.0 μg/g, SD: 1215.0 
μg/g, range: 25.0-5000.0 μg/g) and healthy controls (median: 25 
μg/g, mean: 36.0 μg/g, SD: 23.0 μg/g, range: 25.0-3000.0 μg/g).
Pregnant Subjects
In the pregnant subpopulation, 20 samples were from women in 
their first trimester, 11 samples were from women in the second, 
and 27 samples were from women in the third. Stool samples were 
collected from 10 of 48 pregnant subjects in the first, second, and 
third trimester. Ten gemini gravidities, two Rh-incompatibilities, 
and four other obstetric disorders were observed. In the pregnant 
group, four subjects had hypothyreosis, five had diabetes mellitus, 
three had hypertension, one had asthma, and one had hypercho-
lesterinemia. With regard to FC concentration, healthy controls 
and pregnant subjects with the abovementioned diseases (me-
dian: 28 μg/g, mean: 40.0 μg/g, SD: 24.0 μg/g, range: 25.0-3000.0 
μg/g) were compared with healthy controls and pregnant pa-
tients without any disease (median: 25 μg/g; mean: 34.0 μg/g; SD: 
23.0 μg/g, range: 25.0-150.0 μg/g), and no significant difference 
was observed. Mean FC concentration was 32.5 μg/g (median: 25 
μg/g, SD: 20.4 μg/g, range: 25.0-106.0 μg/g) in women in the first 
trimester, 30.4 μg/g (median: 25 μg/g, SD: 9.9 μg/g, range: 25.0-
52.0 μg/g) in the second trimester, 43.6 μg/g (median: 30 μg/g, SD: 
31.5 μg/g, range: 25.0-138.0 μg/g) in the third trimester (Table 2). 
We did not find significant difference (p<0.092) between FC con-
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 Healthy  Patients Patients 
 non- Healthy with with 
 pregnant pregnant active inactive 
Enrolled women  women IBD IBD 
subjects n=24 n=48 n=40 n=23
Mean age (±SD), years 33.1 (5.2) 35.9 (5.2) 39.6 (15.0) 42.0 (13.9)
Mean FC (±SD, ug/g) 34.1 (27.5) 36.9 (20.4) 1146.5 (1411.1) 179.3 (187.2)
Mean CRP (±SD, mg/l) 4.3 (3.9) 6.0 (4) 13.4 (16.1) 8.8 (17.2)
FC: fecal calprotectin; CRP: C-reactive protein; IBD: inflammatory bowel disease; SD: standard 
deviation
Table 1. Summary of age, FC concentration, and CRP level in healthy 
controls, healthy pregnant subjects, patients with active IBD, and patients 
with inactive IBD
  1st 2nd 3rd 
No. of trimester trimester trimester 
subjects n=20 n=11 n=27 Σ
FC level (ug/g) 
Mean  32.5 30.4 43.6 36.9
Median 25 25 30 25
SD  20.4 9.9 31.5 20.4
Range  25-106 25-52 25-3000 25-3000
CRP (mg/L)  
Mean  6.6 4.6 5.0 6.0
SD  5.8 1.8 3.6 4.0
Range  1-16.7 2.4-7.9 1-12.8 1-16.7
FC: fecal calprotectin; CRP: C-reactive protein; SD: standard deviation
Table 2. FC and serum CRP levels during pregnancy
O
ri
gi
na
l A
rt
ic
le
centrations in different trimesters during pregnancy (Figure 1). 
Overall, the mean FC concentration was 36.9 μg/g (median: 25 
μg/g, SD: 20.4 μg/g, range: 25.0-3000 μg/g) in pregnant women 
and did not differ significantly from that of non-pregnant healthy 
women (p=0.99). One gemini pregnant woman without IBD had 
outstandingly high FC concentration (3000 ug/g). She was diag-
nosed with Rh-incompatibilities (mother: A Rh-negative, “A fetus”: 
AB Rh-negative, “B fetus”: A Rh-positive); in addition, she had type I 
diabetes mellitus. After delivery, we could not follow her up.
Female	Patients	with	IBD
Among IBD patients, 36 had CD and 27 UC. The majority of patients 
(n=54) were under treatment at the time of study enrolment (Table 
3). Eight active and one inactive IBD patients did not undergo ther-
apy; however, these active IBD patients were previously in remis-
sion and came to consultation due to flare-up of symptoms. The 
mean CDAI was 211.7 points (SD: 73.5 points) in active CD and 87 
points (SD: 26.7 points) in inactive CD. The mean pMayo subscore 
was 4.6 points (SD: 2.0 points) and 0.8 points (SD: 0.8 points) in ac-
tive and inactive UC, respectively. In patients with active IBD, mean 
FC concentration was 1146.5 μg/g (median: 430 μg/g, SD: 1411.1 
μg/g, range: 25.0-5000.0 μg/g), whereas in patients in clinical remis-
sion, it was 179.3 μg/g (median: 127 μg/g, SD: 187.2 μg/g, range: 
25.0-770.0 μg/g) (p<0.001). The mean FC concentration was 592.0 
μg/g (median: 251 μg/g, SD: 836.3 μg/g, range: 25.0-3100.0 μg/g) 
in CD and 1041.5 μg/g (median: 300 μg/g, SD: 1558.0 μg/g, range: 
25.0-5000.0 μg/g) in UC patients. Among relapsed CD patients, the 
mean FC concentration was 877.9 μg/g (median: 500 μg/g, SD: 
1007.7 μg/g, range: 25.0-3100.0 μg/g), whereas in patients in remis-
sion, it was 210.7 μg/g (median: 148 μg/g, SD: 218.7 μg/g, range: 
25.0-770.0 μg/g). The mean FC was 1429.3 μg/g (median: 430 μg/g, 
SD: 1722.6 μg/g, range: 25.0-5000.0 μg/g) and 120.5 μg/g (median: 
108.5 μg/g, SD: 91.3 μg/g, range: 25.0-300.0 μg/g) in active and 
inactive UC patients, respectively. FC concentration was signifi-
cantly higher in active IBD patients than in pregnant (p<0.001) and 
non-pregnant healthy women (p<0.001). Our results showed no 
significant difference between FC concentrations of inactive IBD 
patients and healthy controls (p=0.99). Furthermore, no significant 
difference was revealed between FC concentrations of inactive IBD 
patients and pregnant women (p=0.99).
CRP in Assessed Subgroups
Mean CRP levels were 6.6 mg/L (SD: 5.8 mg/L, range: 1-16.7 
mg/L), 4.6 mg/L (SD: 1.8 mg/L, range: 2.4-7.9 mg/L), and 5.0 
mg/L (SD: 3.6 mg/L, range: 1-12.8 mg/L) in pregnant women 
in different trimesters, 13.4 mg/L (SD: 16.1 mg/L, range: 1-56.3 
mg/L) in active and 8.8 mg/L (SD: 17.2 mg/L, range: 1-73.5 
mg/L) in inactive IBD. No significant difference was observed 
between healthy pregnant and non-pregnant women (p=0.8), 
patients with inactive IBD and non-pregnant women (p=0.4), 
patients with inactive IBD and pregnant women (p=0.38); how-
ever, we found that patients with active IBD have significantly 
higher CRP levels than pregnant women (p<0.01).
DISCUSSION
In this prospective study, we aimed to confirm whether FC con-
centration changes during pregnancy and found that it did not 
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Figure 1. Bar chart with mean (SD) value. No significant difference 
(p<0.092) was found between FC levels in different trimesters during 
pregnancy
FC: fecal calprotectin
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Figure 2. Boxplot with median, quartiles and min-max values of FC levels 
in assessed groups. FC was significantly higher in active IBD compared 
with pregnant (p<0.001) and non-pregnant healthy women (p<0.001)
FC: fecal calprotectin; IBD: inflammatory bowel disease
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No. of  Active IBD Inactive IBD CD patients UC patients 
subjects  (n=40)  (n=23)  (n=36)  (n=27)
No therapy 8 1 3 6
Aminosalicylates 13 6 7 12
Corticosteroids 6 0 5 1
Thiopurines 17 8 19 6
Anti-TNF agents 8 8 14 2
Antibiotics 1 1 2 0
Topical therapy 4 5 4 5
IBD: inflammatory bowel disease; CD: Crohn’s disease; UC: ulcerative colitis
Table 3. Treatment of IBD patients. Majority of the patients were under 
therapy at the time of enrollment
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differ between non-pregnant and pregnant women (Figure 2). 
Levels of inflammatory markers are commonly modified in 
pregnancy; however, FC and CRP may be useful indicators of 
relapse in IBD during pregnancy. Mechanisms such as anabolic 
metabolism and changes in hepatic and renal clearance result 
in physiological changes of laboratory parameters (6). Hemo-
dilution can explain changes in hemoglobin and albumin lev-
els, and these parameters may  decreases with progression of 
pregnancy (7). Iron deficiency is also common and should not 
be used as a marker of blood loss (7). Erythrocyte sedimenta-
tion rate (ESR) is commonly accelerated, and physiological leu-
kocytosis is up to 15000 cells/μL (6). On the other hand, non-
invasive techniques have great use in defining disease activity 
in IBD during pregnancy due to the limited use of endoscopic 
procedures in this population. Recently, FC is one of the most 
important markers of relapse, and our results confirmed that 
FC was significantly higher in active IBD than in healthy preg-
nant and non-pregnant women.
Maternal CRP level has been extensively studied as a marker 
of inflammation among pregnant women; however, the utility 
of CRP can only be assessed if effects of normal pregnancy on 
CRP are established. Watts et al. found no consistent changes 
in CRP levels with gestational age (8), although CRP level has 
been reported to be higher in pregnancy, even in uncompli-
cated cases (9). We did not find any difference in CRP levels be-
tween pregnant and non-pregnant patients. Several additional 
analyses have been conducted to examine the associations 
between CRP and pre-eclampsia/eclampsia. CRP level was 
higher in established pre-eclampsia than in normal pregnant 
women (10); furthermore, higher CRP level was reported as an 
independent factor of pre-eclampsia (11); therefore, it should 
be taken into consideration when using CRP as a biomarker.
Serum calprotectin as an indicator of systemic inflammatory 
response was previously evaluated in complicated pregnan-
cies, such as those accompanied by hypertension, pre-eclamp-
sia, and diabetes mellitus. Sugulle et al. (12) reported significant 
difference in median plasma calprotectin concentrations be-
tween healthy subjects and women with gestational diabetes 
mellitus, and serum calprotectin was elevated in pre-eclampsia 
as well. Serum CRP level was higher in patients with gestational 
diabetes than in controls. Calprotectin analysis may be more 
favorable from fecal samples. Jost et al. (13) assessed micro-
biota composition with quantitative polymerase chain reac-
tion and pyrosequencing in healthy subjects in the pre- and 
post-partum period, and results demonstrated that maternal 
microbiota remained stable over the perinatal period with only 
low-grade inflammation shown by FC levels.
In recent years, a few studies assessed the utility of FC in IBD 
during pregnancy, most of which were not published as full pa-
pers (14-17); however, more and more data reported indicate 
the importance of this topic. Results are conflicted, with some 
showing that FC has poor diagnostic accuracy in predicting 
relapse (14) and no correlation being noted between FC and 
pMayo score and Harvey Bradshaw Index (15); however, the 
sensitivity and specificity of FC in determining disease activity 
were 81.8% and 80.7%, respectively (14). In the study by Huang 
et al. (16) 17 pre-conception and pregnant IBD subjects were 
enrolled, and they found that FC concentration was higher in 
clinically active disease and in UC patients throughout preg-
nancy as well. In a prospective Israeli study (17) with over 80 
samples from pregnant IBD patients, FC correlated with CDAI 
and pMayo score. Interestingly, CDAI score correlated weakly 
with ESR and CRP in the CD group; however, for those with in-
flammatory presentation, the correlation became more signifi-
cant. Of note, the same work group previously reported on the 
limitation of using FC; they found no correlation between FC 
and clinical scores as well as between albumin levels and in-
flammatory serum parameters (15). The influence of pregnancy 
on symptoms as well as the physiological effects of pregnancy 
on serum parameters should also be taken into consideration 
when assessing clinical activity indices. Correia et al. (7) estab-
lished that FC concentration did not differ during the trimes-
ters of pregnancy; in addition, FC showed no correlation with 
clinical scores, albumin levels, ESR, and CRP levels.
The main limitation of this study was the low number of preg-
nant subjects when subdivided in trimesters; however, to our 
knowledge, this is the first full paper that assesses FC in healthy 
pregnant women. To summarize, our results revealed that FC 
concentration did not change during pregnancy in healthy 
women; by contrast, it elevated in active IBD, suggesting that FC 
may be a useful noninvasive marker for controlling disease activ-
ity in pregnant IBD patients, if CRP is not elevated. Nevertheless, 
further studies are needed to examine the prognostic role of FC 
and influential factors on FC in pregnant women with IBD.
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